SERPINE1 and breast cancer: The American Society of Clinical Oncology (ASCO) recommended using an ELISA test to measure uPA and PAI-1 levels as prognostic markers for assessing the risk of breast cancer and a predictive marker to determine the suitable adjuvant therapies for the patients [33].